Directorate Change

20 September 2024

Syncona Limited

John Roche Appointed as a Non-Executive Director

Syncona Ltd, (the "Company"), a leading life science investor focused on creating, building and scaling a portfolio of global leaders in life science, announces the appointment of John Roche as an independent Non-Executive Director, with effect from 1 October 2024.

John brings many years of broad financial experience to the role, having spent more than 15 years as a Partner at PricewaterhouseCoopers ("PwC") in Guernsey. During this time he served as managing partner of the Guernsey office for seven years and was leader of the Capital Markets Practice for twelve years. While at PwC, John specialised in providing audit and capital markets advisory services to listed investment companies and alternative asset management clients, developing extensive valuation experience.

John is a Fellow of the Institute of Chartered Accountants in Ireland, who retired from practice in 2022. He is a Non-Executive Director and Chair of the Audit Committee of Riverstone Energy Limited, a London-listed investment company, and a Guernsey resident.

On appointment, John will join the Company's Audit Committee.

Melanie Gee, Chair of Syncona Ltd, said: "We are delighted to welcome John to Syncona. He brings significant financial experience to the Board, and we look forward to benefitting from his breadth of knowledge and expertise as we support the Syncona team to deliver our long-term strategy and growth ambitions."

John Roche said: "I am delighted to be joining Syncona. I look forward to working closely with my Board colleagues and the broader Syncona team as they continue to invest to extend and enhance human life."

No further details are required to be disclosed under UKLR 6.4.8R.

Enquiries

Syncona Ltd

Natalie Garland-Collins / Fergus Witt

Tel: +44 (0) 20 3981 7912

About Syncona

Syncona's purpose is to invest to extend and enhance human life. We do this by creating, building and scaling companies to deliver transformational treatments to patients in areas of high unmet need.

We aim to build and maintain a diversified portfolio of 20-25 globally leading life science businesses, across development stage, modality and therapeutic area, for the benefit of all our stakeholders. We focus on developing treatments that deliver patient impact by working in close partnership with world-class academic founders and experienced management teams. Our balance sheet underpins our strategy, enabling us to take a long-term view as we look to improve the lives of patients with no or poor treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders.

Syncona Limited seeks to achieve returns over the long term. Investors should seek to ensure they understand the risks and opportunities of an investment in Syncona Limited, including the information in our published documentation, before investing.